Our top pick for
Building a portfolio
LivaNova PLC is a medical devices business based in the US. LivaNova shares (LIVN) are listed on the NASDAQ and all prices are listed in US Dollars. LivaNova employs 4,000 staff and has a trailing 12-month revenue of around USD$952.3 million.
|Latest market close||USD$66.21|
|52-week range||USD$33.4 - USD$80.75|
|50-day moving average||USD$57.6124|
|200-day moving average||USD$51.1759|
|Wall St. target price||USD$72.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.41|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-13)||-1.62%|
|1 month (2020-12-23)||-1.81%|
|3 months (2020-10-20)||23.30%|
|6 months (2020-07-20)||22.41%|
|1 year (2020-01-19)||N/A|
|2 years (2019-01-19)||N/A|
|3 years (2018-01-19)||83.81|
|5 years (2016-01-20)||23.80%|
Valuing LivaNova stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LivaNova's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LivaNova's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0239. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LivaNova's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
LivaNova's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$18.4 million.
The EBITDA is a measure of a LivaNova's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$952.3 million|
|Gross profit TTM||USD$731.6 million|
|Return on assets TTM||-0.81%|
|Return on equity TTM||-14.59%|
|Market capitalisation||USD$3.3 billion|
TTM: trailing 12 months
There are currently 3.4 million LivaNova shares held short by investors – that's known as LivaNova's "short interest". This figure is 28.1% up from 2.7 million last month.
There are a few different ways that this level of interest in shorting LivaNova shares can be evaluated.
LivaNova's "short interest ratio" (SIR) is the quantity of LivaNova shares currently shorted divided by the average quantity of LivaNova shares traded daily (recently around 499653.33333333). LivaNova's SIR currently stands at 6.9. In other words for every 100,000 LivaNova shares traded daily on the market, roughly 6900 shares are currently held short.
However LivaNova's short interest can also be evaluated against the total number of LivaNova shares, or, against the total number of tradable LivaNova shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case LivaNova's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 LivaNova shares in existence, roughly 70 shares are currently held short) or 0.0813% of the tradable shares (for every 100,000 tradable LivaNova shares, roughly 81 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against LivaNova.
Find out more about how you can short LivaNova stock.
We're not expecting LivaNova to pay a dividend over the next 12 months.
Over the last 12 months, LivaNova's shares have ranged in value from as little as $33.4 up to $80.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LivaNova's is 0.7454. This would suggest that LivaNova's shares are less volatile than average (for this exchange).
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC has a research collaboration with Verily to gain insights into Vagus nerve stimulation impact on difficult-to-treat depression. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.